Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab.
anti-HER2
axillary lymph nodes dissection
breast cancer
breast cancer related lymphedema
chemotherapy
extranodal extension
lymphovascular invasion
radiation therapy
taxanes
therapy
trastuzumab
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Jan 2019
24 Jan 2019
Historique:
received:
05
12
2018
revised:
22
01
2019
accepted:
22
01
2019
entrez:
27
1
2019
pubmed:
27
1
2019
medline:
27
1
2019
Statut:
epublish
Résumé
Breast cancer related lymphedema (BCRL) is frequent but strategies for an individualized risk assessment are lacking. We aimed to define whether tumor-specific pathological features, coupled with clinical and therapeutic data, could help identify patients at risk. Data from 368 patients with node-positive breast cancers were retrospectively collected, including 75 patients with BCRL (0.4⁻25.6 years follow-up). BCRL was assessed during the standard follow-up oncology visits using the circumferential measurement. Clinicopathologic and therapeutic factors associated with BCRL were integrated into a Cox proportional hazards regression model. Lymphovascular invasion (LVI) was more common in BCRL patients (
Identifiants
pubmed: 30682851
pii: jcm8020138
doi: 10.3390/jcm8020138
pmc: PMC6406664
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Breast. 2019 Apr;44:15-23
pubmed: 30580170
J Clin Oncol. 1998 Oct;16(10):3426-32
pubmed: 9779722
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Gland Surg. 2018 Aug;7(4):379-403
pubmed: 30175055
Future Oncol. 2014;10(9):1649-57
pubmed: 25145433
JNCI Cancer Spectr. 2018 Dec 13;2(4):pky056
pubmed: 31360876
Int J Clin Oncol. 2013 Aug;18(4):607-13
pubmed: 22763660
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Anticancer Drugs. 2017 Mar;28(3):350-355
pubmed: 27997437
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Breast Cancer Res Treat. 2013 Nov;142(1):59-67
pubmed: 24122390
Breast Cancer Res Treat. 2016 Aug;159(1):1-14
pubmed: 27460637
Breast Cancer Res Treat. 2015 Jun;151(2):393-403
pubmed: 25940996
Eur J Cancer Care (Engl). 2010 Mar;19(2):145-66
pubmed: 19674072
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
Clin Genet. 2014 Jul;86(1):62-7
pubmed: 24635704
Ann Surg. 2007 Mar;245(3):452-61
pubmed: 17435553
J Clin Oncol. 2016 Feb 20;34(6):611-35
pubmed: 26644543
Ann Surg Oncol. 2009 Jul;16(7):1959-72
pubmed: 19365624
Lymphology. 2007 Mar;40(1):26-34
pubmed: 17539462
Ann Oncol. 2010 May;21(5):955-60
pubmed: 19940005
Arch Phys Med Rehabil. 2011 Apr;92(4):603-10
pubmed: 21440706
J Clin Oncol. 2005 Oct 1;23(28):7089-97
pubmed: 16192592
World J Gastroenterol. 2016 Sep 21;22(35):7926-37
pubmed: 27672288
Lymphat Res Biol. 2014 Dec;12(4):282-8
pubmed: 25411764
Ann Oncol. 2008 Aug;19(8):1393-1401
pubmed: 18385202
Ann Surg Oncol. 2014 Sep;21(9):2897-903
pubmed: 24777858
Pathol Annu. 1983;18 Pt 2:215-32
pubmed: 6674861
Eur J Cancer. 2006 Feb;42(3):357-62
pubmed: 16377180
Phys Ther. 2016 Dec;96(12):1965-1981
pubmed: 27340195
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
BMC Cancer. 2018 Sep 29;18(1):935
pubmed: 30268112
Eur J Cancer Care (Engl). 2013 Mar;22(2):196-201
pubmed: 23320995
PLoS One. 2015 Dec 16;10(12):e0144923
pubmed: 26674347
Cancer. 1998 Dec 15;83(12 Suppl American):2798-802
pubmed: 9874400
J Dermatol Sci. 2013 Sep;71(3):184-94
pubmed: 23706492
Ann Surg Oncol. 2011 Oct;18(10):2866-72
pubmed: 21465310
Breast Care (Basel). 2016 Feb;11(1):45-50
pubmed: 27051396
Cancer. 2000 Feb 1;88(3):608-14
pubmed: 10649254
Br J Surg. 2015 Aug;102(9):1071-8
pubmed: 26040263